Scorpion Therapeutics Entered into an Exclusive Collaboration and License Agreement with Pierre Fabre to Co-Develop and Commercialize STX-721 and STX-241
Shots:
- Scorpion will receive $65M up front, ~$553M upon achievement of milestones along with royalties on annual net sales of each licensed product in territories excl. US, Canada & Japan. Pierre Fabre will receive royalties based on annual net sales of each licensed product in the US
- Scorpion gets commercialization rights to STX-721 & STX-241 in the US, Canada & Japan and will be responsible for the clinical development of STX-721. Pierre Fabre obtains rights in all other global territories & will lead the clinical development & commercialization activities of STX-241 in all other territories with a focus on the EU & China
- Both companies will share global development expenses based on a pre-specified cost-sharing arrangement. STX-721 & STX-241 are currently advancing through preclinical studies & IND submission to the US FDA is expected in mid-23 & H1’24
Ref: scorpion therapeutics and pierre fabre | Image: scorpion therapeutics and pierre fabre
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
